false
Hamburger Menu
Catalog
FDA Approval: Adagrasib for KRAS G12C NSCLC
FDA Approval: Adagrasib for KRAS G12C NSCLC
Podcast | English | 2022 | 30 Min
Create Account
Credit
No Credit Offered
Summary
This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla (@SheenaBhallaMD), assistant professor of Medicine and Thoracic Oncologist at UT Southwestern Medical Center in Dallas.
Faculty
Podcast Hosts:
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA
Podcast Guests:
Sheena Bhalla, MD, Assistant Professor in the Department of Internal Medicine, UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas, TX
Joshua Sabari, MD, Director Inpatient Medical Oncology, NYU Langone Health, New York, NY, USA
×
FDA Approval: Adagrasib for KRAS G12C NSCLC Course List
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English